Insulin Preparation With Vasoactive Agents for Faster Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current short-acting insulin analogues (SAIA) therapies for type 2 diabetes (T2D) patients, who are often obese and insulin-resistant, do not consistently improve glycemic control, increasing the risk of cardiovascular diseases and other complications.
Innovation Solution
Simultaneously administering a therapeutically effective amount of insulin and a subcutaneously effective amount of vasoactive agents to the same site, enhancing subcutaneous insulin absorption and blood flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If short-acting insulin analogues (SAIA) are administered to T2D patients, then absorption speed is improved, but glycemic control consistency deteriorates
Solution Approach 1:
The patent changes the physiological parameters of the absorption site by using vasoactive agents to modify blood flow characteristics. This transforms the absorption environment from a static, variable state to a dynamically controlled state with enhanced and consistent blood flow, thereby improving both absorption speed and glycemic control consistency simultaneously
Solution Approach 2:
The vasoactive agent acts as an intermediary substance that mediates between the insulin injection and the bloodstream. It enhances the absorption process by actively modifying local blood flow conditions, serving as a catalyst that improves both the speed and reliability of insulin delivery without being consumed in the process
2Reliability
If insulin dosage is increased for obese T2D patients, then glycemic control is improved, but cardiovascular risk increases
Solution Approach 1:
The patent changes the absorption rate parameter by introducing vasoactive agents that enhance blood flow at the injection site. This allows achieving better glycemic control with lower insulin doses by improving the efficiency of insulin delivery and utilization, thereby reducing the harmful effects associated with high-dose insulin therapy
3Speed
If vasoactive agents are administered to enhance insulin absorption, then absorption speed is improved, but treatment complexity increases
Solution Approach 1:
The patent merges the insulin therapy with vasoactive agent administration into a single integrated treatment approach. By combining these substances in a unified formulation or co-administration protocol, the treatment leverages the synergistic effects of both components without requiring separate complex delivery systems or procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Accelerates insulin absorption and hypoglycemic action, reducing the risk of diabetes complications by improving glycemic control in obese T2D patients.
Implementation Method 1
it has surprisingly been found that subcutaneous administration of a vasoactive agent... increases subcutaneous blood flow and insulin absorption
Data Source
AI summary
Applicant has amended the specification to include an Abstract. No new matter is added by way of this amendment. Applicant submits that this amendment addresses each of the informalities requiring correction listed in the Notice to File Corrected Application Papers. If the Examiner believes, for any reason, that personal communication will expedite examination of this application, the Examiner is invited to telephone the undersigned at the number provided.No additional fees are believed due in connection with this submission. However, in the event that additional fees are due, the Commissioner is hereby authorized by this paper to charge any additional fees associated with this submission or credit any overpayment to Deposit Account No. 05-0840, Eli Lilly and Company, associated with Customer No. 25885. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 CFR 1.17 and should be treated as a constructive petition for an extension of time in this submission pursuant to 37 CFR 1.136.